Publication Name	World Journal of Gastroenterology
Manuscript ID	8993
Country	Jordan

Received	2014-01-16 11:43
Peer-Review Started	2014-01-16 17:07
To Make the First Decision	2014-02-28 17:54
Return for Revision	2014-03-07 21:21
Revised	2014-03-23 20:24
Second Decision	2014-06-05 10:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-05 10:57
Articles in Press	2014-06-05 11:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-10 09:05
Publish the Manuscript Online	2014-07-21 17:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies
Manuscript Source	Invited Manuscript
All Author List	Khaled A Jadallah, Susan M Kullab and David S Sanders
Funding Agency and Grant Number
Corresponding Author	Khaled A Jadallah, MD, Assistant Professor of Medicine, Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan. khaled-j@just.edu.jo
Key Words	Constipation; Irritable bowel syndrome; Drug therapy; Serotonergic agents; Prokinetics; 5-hydroxytryptamine type 4 agonists; Secretagogues; Prosecretory agents; Bile acid modulators
Core Tip	Constipation-predominant irritable bowel syndrome (IBS-C) is one of the most common disorders seen by gastroenterologists worldwide, and is associated with a substantial burden on health care resources. Pharmacologic treatments for IBS-C have largely been unsatisfactory, mainly due to the multifaceted and poorly understood pathophysiology of this disorder. Recently approved drugs and novel investigational compounds are expected to streamline the management of IBS-C. This narrative review covers the mechanisms, clinical trial efficacies, and safety profiles of these pharmacologic agents, in order to help practicing physicians keep up with the rapidly developing field of IBS-C therapy.
Publish Date	2014-07-21 17:17
Citation	Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies. World J Gastroenterol 2014; 20(27): 8898-8909
URL	http://www.wjgnet.com/1007-9327/full/v20/i27/8898.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i27.8898

Full Article (PDF)	WJG-20-8898.pdf
Full Article (Word)	WJG-20-8898.doc
Manuscript File	8993-Review.docx
Answering Reviewers	8993-Answeing reviewers.pdf
Copyright License Agreement	8993-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	8993-Language certificate.pdf
Peer-review Report	8993-Peer reivew(s).pdf
Scientific Misconduct Check	8993-CrossCheck.jpg
Scientific Editor Work List	8993-Scientific editor work list.pdf